相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors
P. A. Cassier et al.
ANNALS OF ONCOLOGY (2014)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence
R. A. Wells et al.
CURRENT ONCOLOGY (2014)
Cancer genomics identifies disrupted epigenetic genes
Laia Simo-Riudalbas et al.
HUMAN GENETICS (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
Gautam Sethi et al.
MOLECULAR CANCER (2014)
Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA
Toni Pfaffeneder et al.
NATURE CHEMICAL BIOLOGY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis
M. Rodriguez-Paredes et al.
ONCOGENE (2014)
A Novel Curcumin Analog (H-4073) Enhances the Therapeutic Efficacy of Cisplatin Treatment in Head and Neck Cancer
Bhavna Kumar et al.
PLOS ONE (2014)
Study to Evaluate Molecular Mechanics behind Synergistic Chemo-Preventive Effects of Curcumin and Resveratrol during Lung Carcinogenesis
Anshoo Malhotra et al.
PLOS ONE (2014)
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Kyle D. Konze et al.
ACS CHEMICAL BIOLOGY (2013)
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells
Ziyan Lu et al.
ANTI-CANCER DRUGS (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Aniruddha J. Deshpande et al.
BLOOD (2013)
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
Jennifer E. Amengual et al.
BLOOD (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition
Michael D. Amatangelo et al.
CELL CYCLE (2013)
A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
Balaji Venugopal et al.
CLINICAL CANCER RESEARCH (2013)
GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia
T. Holmlund et al.
LEUKEMIA (2013)
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain
Lindsey I. James et al.
NATURE CHEMICAL BIOLOGY (2013)
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases
Fanny L. Cherblanc et al.
NATURE CHEMICAL BIOLOGY (2013)
Quercetin Enhances the Antitumor Activity of Trichostatin A through Upregulation of p53 Protein Expression In Vitro and In Vivo
Shu-Ting Chan et al.
PLOS ONE (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma
Yuan Yuan et al.
ACS CHEMICAL BIOLOGY (2012)
Emerging Roles of Anacardic Acid and Its Derivatives: A Pharmacological Overview
Mahadevappa Hemshekhar et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
Ke Gong et al.
BIOCHEMICAL JOURNAL (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor
Dominica Willmann et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
H. Chaib et al.
LEUKEMIA (2012)
Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
A. Vilas-Zornoza et al.
LEUKEMIA (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Genetic Events That Shape the Cancer Epigenome
Russell J. H. Ryan et al.
SCIENCE (2012)
Discovery of HDAC Inhibitors That Lack an Active Site Zn2+-Binding Functional Group
Chris J. Vickers et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Wenyu Yu et al.
NATURE COMMUNICATIONS (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Inhibitors of histone demethylases
Brian Lohse et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia
Jin He et al.
BLOOD (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Euan A. Stronach et al.
CANCER RESEARCH (2011)
Novel Histone Demethylase LSD1 Inhibitors Selectively Target Cancer Cells with Pluripotent Stem Cell Properties
Jing Wang et al.
CANCER RESEARCH (2011)
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
Masashi Takawa et al.
CANCER SCIENCE (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Chemogenetic Analysis of Human Protein Methyltransferases
Victoria M. Richon et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Inhibition of Histone Demethylases by 4-Carboxy-2,2′-Bipyridyl Compounds
Kai-Hsuan Chang et al.
CHEMMEDCHEM (2011)
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation
Hao Wu et al.
GENES & DEVELOPMENT (2011)
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers
Shinya Hayami et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Small-Molecule Ligands of Methyl-Lysine Binding Proteins
J. Martin Herold et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
Frederic R. Santer et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Role of Androgen Receptor and Associated Lysine-Demethylase Coregulators, LSD1 and JMJD2A, in Localized and Advanced Human Bladder Cancer
Eric C. Kauffman et al.
MOLECULAR CARCINOGENESIS (2011)
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Craig J. Ceol et al.
NATURE (2011)
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi et al.
NATURE CHEMICAL BIOLOGY (2011)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Jaime Coronel et al.
MEDICAL ONCOLOGY (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
A decade of exploring the cancer epigenome - biological and translational implications
Stephen B. Baylin et al.
NATURE REVIEWS CANCER (2011)
Oxidation of amines by flavoproteins
Paul F. Fitzpatrick
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Sirtuin chemical mechanisms
Anthony A. Sauve
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Jerome C. Bressi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Nina Wagener et al.
BMC CANCER (2010)
Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor
Erin M. Bowers et al.
CHEMISTRY & BIOLOGY (2010)
Structural studies on human 2-oxoglutarate dependent oxygenases
Michael A. McDonough et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2010)
In Vivo Residue-specific Histone Methylation Dynamics
Barry M. Zee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Demystified molecular pathology of NUT midline carcinomas
Christopher A. French
JOURNAL OF CLINICAL PATHOLOGY (2010)
Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
David Moffat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway
Shinya Hayami et al.
MOLECULAR CANCER (2010)
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Veronica Novotny-Diermayr et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
Sundar Jagannath et al.
LEUKEMIA RESEARCH (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Gorica Nikoloski et al.
NATURE GENETICS (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation
Sohail Malik et al.
NATURE REVIEWS GENETICS (2010)
Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors
Oliver N. F. King et al.
PLOS ONE (2010)
Fast signals and slow marks: the dynamics of histone modifications
Teresa K. Barth et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Polycomb group protein-mediated repression of transcription
Lluis Morey et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis
Aron Gyuris et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2009)
BisubstrateInhibitors of the MYST HATs Esa1 and Tip60
Jiang Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Janine Arts et al.
CLINICAL CANCER RESEARCH (2009)
Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes
Yi Huang et al.
CLINICAL CANCER RESEARCH (2009)
An operational definition of epigenetics
Shelley L. Berger et al.
GENES & DEVELOPMENT (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
Yanqi Chang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer
G. Liu et al.
ONCOGENE (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
What controls nucleosome positions?
Eran Segal et al.
TRENDS IN GENETICS (2009)
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Xin Liu et al.
NATURE (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Multivalent engagement of chromatin modifications by linked binding modules
Alexander J. Ruthenburg et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers
Sean D. Taverna et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination
Min Gyu Lee et al.
SCIENCE (2007)
Characterization of novel inhibitors of histone acetyltransferases
Elena D. Eliseeva et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression
Fei Lan et al.
NATURE (2007)
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA
Steen K. T. Ooi et al.
NATURE (2007)
The role of histone deacetylases (HDACs) in human cancer
Santiago Ropero et al.
MOLECULAR ONCOLOGY (2007)
Specific inhibition of p300-HAT alters global gene expression and represses HIV replication
K. Mantelingu et al.
CHEMISTRY & BIOLOGY (2007)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes
Yi Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
L3MBTL1, a histone-methylation-dependent chromatin lock
Patrick Trojer et al.
CELL (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
Hoon Ryu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence
Philip Kahl et al.
CANCER RESEARCH (2006)
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer
Ling Geng et al.
CANCER RESEARCH (2006)
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Paul A. C. Cloos et al.
NATURE (2006)
Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases
Johnathan R. Whetstine et al.
CELL (2006)
Comprehensive genomic analysis of desmoplastic medulloblastomas:: identification of novel amplified genes and separate evaluation of the different histological components
A Ehrbrecht et al.
JOURNAL OF PATHOLOGY (2006)
Histone demethylation by a family of JmjC domain-containing proteins
Y Tsukada et al.
NATURE (2006)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications
Min Gyu Lee et al.
CHEMISTRY & BIOLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
L Stimson et al.
MOLECULAR CANCER THERAPEUTICS (2005)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein brd4
ZY Yang et al.
MOLECULAR CELL (2005)
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9
D Greiner et al.
NATURE CHEMICAL BIOLOGY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding
J Hu et al.
MOLECULAR CANCER RESEARCH (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia
RJ Greenwald et al.
BLOOD (2004)
Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
DM Lucas et al.
LEUKEMIA (2004)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Transcriptional regulation in acute promyelocytic leukemia
RJ Lin et al.
ONCOGENE (2001)
Deacetylation of p53 modulates its effect on cell growth and apoptosis
JY Luo et al.
NATURE (2000)
Structure and function of a human TAFII250 double bromodomain module
RH Jacobson et al.
SCIENCE (2000)
HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF
OD Lau et al.
MOLECULAR CELL (2000)
分享论文
